Vaccine-induced Measles Virus-specific T Cells Do Not Prevent Infection or Disease but Facilitate Subsequent Clearance of Viral RNA
Overview
Affiliations
Infection with wild-type measles virus (MeV) induces lifelong protection from reinfection, and parenteral delivery of the live attenuated measles vaccine (LAV) also provides protection from measles. The level of neutralizing antibody is a good indicator of protection, but the independent roles of MeV-specific antibody and T cells have not been identified. In this study, macaques immunized with LAV through a nebulizer and a mouthpiece developed MeV-specific T-cell responses but not neutralizing antibodies. Upon challenge with wild-type MeV, these animals developed rashes and viremias similar to those in naive animals but cleared viral RNA from blood 25 to 40 days faster. The nebulizer-immunized animals also had more robust MeV-specific CD4(+) and CD8(+) T-cell responses than the naive animals after challenge, characterized by a higher number and better durability of gamma interferon (IFN-γ)-producing cells. Induction of MeV-specific circulating CD4(+) and CD8(+) T cells capable of producing multiple cytokines correlated with clearance of viral RNA in the nebulizer-immunized macaques. These studies demonstrated that MeV-specific T-cell immunity alone did not prevent measles, but T-cell priming enhanced the magnitude, durability, and polyfunctionality of MeV-specific T cells after challenge infection and correlated with more rapid clearance of MeV RNA. IMPORTANCE The components of vaccine-induced immunity necessary for protection from infection and disease have not been clearly identified for most vaccines. Vaccine development usually focuses on induction of antibody, but T-cell-based vaccines are also under development. The live attenuated measles vaccine (LAV) given subcutaneously induces both T cells and neutralizing antibody and provides solid protection from infection. LAV delivered to the upper respiratory tract through a nebulizer and mouthpiece induced a T-cell response but no neutralizing antibody. These T-cell-primed macaques demonstrated no protection from rash or viremia when challenged with wild-type MeV, but viral RNA was cleared more rapidly than in unimmunized animals. Thus, T-cell immunity did not protect from infection or acute disease but facilitated virus clearance during recovery. These studies demonstrate the importance and independent roles of T cells and antibody in protection and recovery from measles.
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity.
Emmelot M, Bodewes R, Maissan C, Vos M, de Swart R, van Els C NPJ Vaccines. 2025; 10(1):36.
PMID: 39979288 PMC: 11842548. DOI: 10.1038/s41541-025-01088-y.
Induction of tissue resident memory T cells by measles vaccine vector.
Vera-Peralta H, Ruffie C, Najburg V, Brione M, Combredet C, Frantz P Hum Vaccin Immunother. 2024; 20(1):2436241.
PMID: 39693193 PMC: 11657113. DOI: 10.1080/21645515.2024.2436241.
Shapiro J, Corrado M, Perry J, Watts T, Bolotin S Hum Vaccin Immunother. 2024; 20(1):2395679.
PMID: 39205626 PMC: 11364080. DOI: 10.1080/21645515.2024.2395679.
Immunogenicity of a peptide-based vaccine for measles: a pilot evaluation in a mouse model.
Quach H, Ratishvili T, Haralambieva I, Ovsyannikova I, Poland G, Kennedy R Sci Rep. 2024; 14(1):18776.
PMID: 39138335 PMC: 11322560. DOI: 10.1038/s41598-024-69825-2.
What's going on with measles?.
Moss W, Griffin D J Virol. 2024; 98(8):e0075824.
PMID: 39041786 PMC: 11334507. DOI: 10.1128/jvi.00758-24.